Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which blood thinner is safer for lung clots? a Head-to-Head test

NCT ID NCT07774273

Disease control Sponsor: Combined military hospital lahore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 25, 2026 · Updated 3 times

Summary

This trial asks whether apixaban or rivaroxaban, two standard blood thinners, causes fewer bleeding problems during the first three months of treatment for acute pulmonary embolism (blood clots in the lungs). About 540 adults with confirmed pulmonary embolism will be randomly assigned to one of the two medications. The study tracks major and clinically relevant minor bleeding episodes to see if one drug offers a safer profile.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
apixaban or rivaroxaban, two oral blood thinners (anticoagulants)
What this could lead to
If one blood thinner causes fewer bleeding complications, it could become the preferred choice for treating acute pulmonary embolism, improving safety for patients.
What could go wrong
This is a single-center trial, so results may not apply broadly. Bleeding risk differences may be small, and the open-label design could introduce bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

540 people

The number who actually took part.

Started

Jan 2021

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * CT pulmonary angiography-confirmed acute PE * Intraluminal pulmonary arterial filling defect Exclusion Criteria: * Hemophilia or other bleeding disorder * Known platelet disorder * Previous major bleeding * Active bleeding * Pregnancy or lactation * Creatinine clearance \< 30 mL/min * Indication for therapeutic anticoagulation other than VTE

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary embolism acute are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary embolism venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary embolism acute Venous thromboembolism (VTE)

Contacts and locations

Locations

  • Combined Military Hospital Lahore

    Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.